Clinical Trial Update: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )

View source ↗

Summary

A completed registry study evaluating HUMIRA (adalimumab) in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Rheumatoid Arthritis, Psoriatic Arthritis | Status: COMPLETED | Results posted: 2019-07-05